Background: To support clinical development of HCV non-structural protein (NS) 3 protease inhibitors (PIs), phenotypic monitoring of patient isolates is a prerequisite for understanding the emergence of resistance. HCV isolates typically fail to replicate in cell culture, necessitating the use of alternative phenotyping methods. Methods: An NS3 protease chimeric replicon system was developed to monitor the phenotype of clinical isolates. The transfer of NS3 protease domain sequences from HCV-infected patients to the background of genotype (Gt) 1a-H77c, 1b-Con1 and 2a-JFH-1 lab strain replicons adapted to highlevel cell culture replication was investigated. Results: NS3 protease sequences derived from HCV Gt 1a or Gt 1b infected patients were transferred into Gt 1a and 1b replicons, respectively. Replication was detected for 20% of Gt 1a and 75% of Gt 1b sequences. Incorporation of known cell culture adaptive change NS3-E176G improved replication of Gt 1b but not of Gt 1a sequences. Transfer of Gt 1a clinical sequences into the Gt 1b background enhanced replication and allowed phenotypic analysis of all sequences. A correlation was observed between clinical isolate sequence polymorphisms and reduced susceptibility to NS3 PI. In mixed populations containing known NS3 PI resistance changes NS3-R155K or D168E/V, sensitivity of resistance detection was ≥10%. Conclusions: An HCV replicon capable of supporting phenotypic characterization of patient-derived HCV NS3 protease sequences was developed. Pre-existence of amino acid changes associated with NS3 PI resistance highlights the need for combination therapies in the treatment of HCV.
Infection with HCV causes acute inflammation of the liver [1] . In approximately 70% of cases infection becomes chronic, predisposing an estimated 170 million carriers worldwide to liver cirrhosis and hepatocellular carcinoma [2] . Improved therapies for HCV are urgently needed. The currently available standard therapy, pegylated interferon-α plus ribavirin (PEG-IFN-α/RBV), is associated with a high incidence of severe adverse effects including fatigue, muscle aches, depression and cognitive impairment, often resulting in poor adherence and premature discontinuation of therapy [3] . In addition, PEG-IFN/RBV has a poor response rate, varying from 40 to 80% depending on the HCV virus genotype [4, 5] .
Recently, a number of promising direct-acting antivirals (DAA) have been discovered [6] . Compounds targeting the serine protease encoded by HCV non-structural protein (NS) 3 have demonstrated suppression of viral replication in early clinical trials [7, 8] . The error-prone nature of the viral RNA-dependent RNA polymerase in conjunction with a rapid rate of viral turnover results in a high degree of sequence heterogeneity. It is therefore not surprising that drug-resistant variants pre-exist or rapidly emerge upon therapy with NS3 protease inhibitors (PIs) in the clinic [8] [9] [10] [11] [12] [13] . Understanding the potential for emergence of resistance to NS3 PIs during clinical trials has become a priority.
Direct culture of clinical isolates, the method of choice for phenotyping some viruses, has proven problematic for HCV. A limited number of full-length HCV sequences have achieved measurable replication in cell culture [14] [15] [16] . The self-replicating HCV subgenomic replicon provides a more reliable means of measuring effects on replication and compound susceptibility, but Introduction only a handful of replicating laboratory strain Gt 1a, Gt 1b, and Gt 2a sequences have been identified (reviewed in [17] ). Qi et al. [18] successfully transferred clinical NS3 protease domain sequences into a laboratory strain replicon, but replication of some Gt 1b and all Gt 1a sequences tested was not robust. Although single amino acid changes can be introduced into laboratory strain replicons for phenotyping, potential contributions from the background sequence may be missed.
In the present study, we identified an HCV replicon capable of supporting robust replication when Gt 1a or Gt 1b clinical isolate NS3 protease domain sequences were introduced. Amino acid sequence polymorphisms among clinical isolates were identified and correlated with a range of susceptibilities to NS3 PI. The resulting system enabled detection of phenotypic variations in a diverse panel of HCV patient isolate sequences.
Methods

Construction of replicon shuttle vectors
Gt 1a (H77c), Gt 1b (Con1) [19] and Gt 2a (JFH-1) replicons were silently modified to introduce unique restriction enzyme sites flanking the NS3 protease domain by PCR using oligonucleotides (Sigma-Genosys, St Louis, MO, USA) described in Additional file 1. The Gt 1a (H77c) shuttle vector was modified to include a unique NdeI site overlapping NS3 amino acid (aa) 7, a unique AsiSI site overlapping aa179-181, and to silently destroy an existing NdeI site. To construct the Gt 1b (Con1) replicon shuttle vector, four existing NcoI sites were silently eliminated, leaving a unique NcoI site overlapping the Met (aa1) of NS3. A unique AsiSI site was introduced overlapping aa179-181 of NS3. For the Gt 2a (JFH-1) replicon shuttle vector, unique 5′ NdeI and 3′ AsiSI sites were introduced as above; three additional NdeI sites were silently eliminated. The NS3 protease domain was disrupted by insertion of a short linker encoding a premature stop codon (Gt 1a, Gt 1b) or an NS3 protease domain deletion (Gt 2a). Modifications were confirmed by fully sequencing all constructs.
Amplification and cloning of HCV sequences
Viral RNA was isolated from serum with a QIA Amp MiniElute Viral Vacuum kit (Qiagen, Valencia, CA, USA). First-strand complementary DNA was synthesized from random hexamer primers with the SuperScript III First-Strand Synthesis System for reverse transcriptase PCR (Invitrogen, Carlsbad, CA, USA). The NS3 protease coding region was amplified with Gt-specific primers. A second PCR with the same or nested internal primers was performed when required to obtain sufficient complementary DNA for sequence analysis. At least two independent PCR products were amplified with different primer sets for each sample. Population sequence data covering both strands were obtained from the purified PCR products. Population patient isolate sequences were PCR amplified using isolate-specific primers with 5′ and 3′ cloning sites added using Platinum Taq HiFi Supermix (Invitrogen), restriction enzyme digested and ligated into shuttle vectors. The population of clones derived from each patient was transformed into Escherichia coli STBL-2 (Invitrogen) and plasmid DNA was purified using the HiSpeed Plasmid Midi Kit (Qiagen).
Transient replication assays
For transcription, plasmid DNA populations from clinical isolates were ScaI digested, treated with 20 µg/ ml proteinase K for 30 min at 50°C, and purified using the Qiaquick PCR Purification Kit (Qiagen). RNA was transcribed in vitro using 1 µg DNA template and the T7 Ribomax Express kit (Promega, Madison, WI, USA). For transfection, 300,000 Huh7.5 cells (Apath, Brooklyn, NY, USA) were plated 1 day prior in six-well plates. RNA (1 µg) was transfected using DMRIE-C (Invitrogen). After 3-4 h incubation (37°C, 5% CO 2 ), trypsinized cells were diluted in Dulbecco's modified Eagle medium containing 10% fetal bovine serum and 2 mM l-glutamine, and seeded in 24-well or 96-well plates with inhibitors (0.5% DMSO, final). Following 4 days of incubation (37°C, 5% CO 2 ), the luciferase signal was measured with the Renilla Luciferase (RLuc) Assay System or the Dual-Glo Luciferase Assay System (Promega) for 24-well 2 and 100 µg/ml ampicillin. Expression of His-NS3/4A was induced at 0.8 optical density (600 nm) by addition of 0.5 mM isopropyl-β-d-thio-galactoside at 20ºC for 22 h. Cells were lysed by sonication in 25 mM HEPES (pH 7.5), 20% glycerol, 500 mM NaCl, 0.5% Triton-X100, 1 µg/ml lysozyme, 5 mM MgCl 2 , 1 µg/ml DNaseI and 5 mM β-mercaptoethanol, and were clarified by ultracentrifugation at 23,500 × g for 1 h at 4ºC. Imidazole was added to the supernatant to a final concentration of 15 mM. Crude supernatant was bound to His affinity resin, washed with 10 volumes of wash buffer (25 mM HEPES pH 7.5, 20% glycerol, 500 mM NaCl, 0.5% Triton-X100, 15 mM imidazole, 5 mM β-mercaptoethanol) and eluted with five volumes of wash buffer containing 200 mM imidazole. The HCV NS3 protease assay buffer and determination of the 50% inhibitory concentration (IC 50 ) was generated as previously described [20] . Enriched, recombinant full-length NS3/4A protease was serially diluted to obtain linear progress rates over 30 min. Reactions consisting of 50 mM HEPES pH 7.5, 150 mM sodium chloride, 15% glycerol, 0.1% Triton X-100, 10 mM DTT and 50 µg/ml bovine serum albumin were initiated by addition of 2.5 µM HCV-FRET peptide substrate [19] . Fluorescence (excitation wavelength 360 nM, emission wavelength 490 nM) was measured in a Cytofluor 4000 (Analytical Biosystems, Foster City, CA, USA).
Results
HCV replicon shuttle vectors
To facilitate cloning of NS3 protease sequences from Gt 1a and Gt 1b clinical isolates, HCV replicon shuttle vectors were constructed in the background of Gt 1a (H77c) and Gt 1b (Con1) cell culture adapted replicons ( Figure 1) . Use of the highly replicating Gt 2a replicon to support replication of Gt 1a or Gt 1b NS3 protease domain chimeras was also investigated (Figure 1 ). Because all substitutions identified to date conferring resistance to NS3 PI map within the N-terminal 181 aa, we chose to modify replicons to accept transfer of the protease domain from clinical isolates. This approach is consistent with the observation that preservation of the laboratory strain NS3 helicase domain improves isolate replication [18] . Unique restriction enzyme sites were silently introduced into each replicon shuttle vector flanking the NS3 protease domain ( Figure 1A, 1C  and 1E ). The sites flank a deletion (Gt 1a and Gt 2a) or truncation (Gt 1b) in the protease domain so that replication was only observed when functional NS3 patient sequences were introduced (see Methods). To monitor transient replication, replicon shuttle vectors were constructed to contain a Renilla luciferase reporter gene downstream of the HCV internal ribosome entry site.
The Gt 1a, Gt 1b and Gt 2a replicon shuttle vectors were tested for their ability to replicate and support replication of intergenotypic chimeras ( Figure 1B , 1D and 1F). In vitro transcribed replicon RNA was transfected into Huh7.5 cells, and luciferase activity monitored as a measure of replication. Figure 1B shows the luciferase signal obtained with DMSO-treated controls relative to that observed when replication was fully inhibited with a NS5A inhibitor. Replication of the Gt 1a replicon with unique 5′-NdeI and 3′-AsiSI sites flanking the NS3 protease domain, clone RLuc1a-S4, was not impaired relative to the original unmodified Gt 1a (H77c) replicon (RLuc1a; Figure 1B ). Intergenotypic chimeras with Gt 1b (Con1; RLuc1a-S4 1b NS3-181) or Gt 2a (JFH-1; RLuc1a-S4 2a NS3-181) NS3 protease domains failed to replicate to detectable levels. For Gt 1b ( Figure 1D ) a replicon shuttle vector with 5′-NcoI and 3′-AsiSI sites flanking the NS3 protease domain, RLuc1b-S3, replicated at a level similar to the unmodified Gt 1b replicon (RLuc1b). A chimera containing the Gt 1a (H77c) NS3 protease domain in the background of the Gt 1b (Con1) replicon (RLuc1b-S3 1a NS3-181) also replicated; replication of a similar chimera with the Gt 2a NS3 protease domain (RLuc1b-S3 2a NS3-181) was not detectable ( Figure 1D ). For Gt 2a ( Figure 1F ), a shuttle vector with unique 5′-NdeI and 3′-AsiSI sites flanking the NS3 protease domain (RLuc2a-S) replicated as well as the unmodified replicon (RLuc2a). No detectable replication was observed for chimeras with the Gt 1a (RLuc2a-S 1a NS3-181) or Gt 1b (RLuc2a-S 1b NS3-181) NS3 protease domains in the background of the Gt 2a replicon ( Figure 1F ). Replicon shuttle vectors with engineered disruptions in the NS3 protease domain (clones RLuc1a-S4 ∆ NS3-181, RLuc1b-S4 ∆ NS3-181 and RLuc2a-S ∆ NS3-181) failed to replicate (Gt 1a and Gt 1b, Additional files 2 and 3; Gt 2a, AKS et al., data not shown), confirming that phenotypic analysis would measure only activity of the introduced clinical isolate NS3 protease domains. 
Ncol AsiSI Figure 1 . Replication of HCV NS3 protease domain intergenotypic chimeras HCV replicons from laboratory reference strains of (A&B) genotype (Gt) 1a (H77c), (C&D) Gt 1b (Con1) or (E&F) Gt 2a-JFH-1 were modified to create shuttle vectors to facilitate insertion of non-structural protein (NS) 3 protease domain sequences from HCV clinical isolates. Modifications, depicted in (A), (C) and (E), are described in detail in Methods. Replicon constructs used in these studies contain a Renilla luciferase reporter gene (RLuc) under control of the HCV internal ribosome entry site, followed by the HCV NS3 through NS5B. NS3 protease domain (P) and helicase domain (H) are indicated. Intergenotypic chimeras were created to test the ability of the replicons to support introduction of Gt 1a or Gt 1b NS3 protease domain sequences. Resulting replicon constructs were transcribed in vitro, transfected into Huh7. Phenotypic analysis of Gt 1a and Gt 1b clinical isolates NS3 protease domains from seven HCV Gt 1a and four Gt 1b infected sera were amplified by reverse transcriptase-PCR to introduce cloning sites, then transferred into the RLuc1a-S4 ∆ NS3-181 and RLuc1b-S4 ∆ NS3-181 shuttle vectors, respectively. The replication capacities of the Gt 1a chimeras were 1-38% relative to the reference strain, Gt 1a (H77c; Figure 2A ). The assay window between uninhibited (DMSO-treated) and fully inhibited (NS5A inhibitor-treated) luciferase signal ranged from <4-fold to 8-fold, relative to 34-fold for Gt 1a (H77c; AKS et al., data not shown; Additional file 4). Replication capacities for the Gt 1b chimeras were 3-56% of Gt 1b (Con1; Figure 2B ); assay windows ranged from <4-fold to 92-fold relative to 260-fold for Gt 1b (Con1; AKS et al., data not shown; Additional file 4).
Clinical isolate chimeras were also tested for susceptibility to NS3 PI (Table 1) . Only Gt 1a isolate chimeras 1a-5 and 1a-9 replicated to sufficient levels for determination of EC 50 values (≥4-fold assay window). EC 50 values were determined for three of four Gt 1b chimeras. While most EC 50 values were close to those obtained for the reference strains, the EC 50 value for isolate 1b-9 was 64-fold higher than that obtained for Gt 1b (Con1).
Strategies to improve replication of clinical isolate sequences
The replicon shuttle vectors were modified to optimize detection of clinical isolate chimera replication. The Gt 1a (H77c) replicon encodes NS3-G176 (HCV polyprotein aa1202) [21] . In the Gt 1b (Con1) background, an NS3-E176G substitution enhances replication [18, 22] . Since the tested Gt 1a and Gt 1b patient isolate sequences (Figure 2A and 2B) all encoded NS3-E176, we investigated whether an NS3-E176G substitution would improve replication. This substitution failed to rescue replication of clinical isolate chimera 1a-1 ( Figure 2C ). By contrast, the NS3-E176G substitution improved replication of poorly replicating Gt 1b chimera, 1b-1, and of Gt 1b (Con1) by >5-fold (Figure 2D ), in agreement with previous reports [18, 22] . Earlier experiments with intergenotypic NS3 protease domain chimeras demonstrated a chimera with Gt 1a (H77c) NS3 protease domain in the Gt 1b (Con1) replicon background replicated as well as parental type Gt 1b (Con1; Figure 1D ), >10-fold higher than the Gt 1a (H77c) reference strain construct rLuc1a (compare Figure 1B and Figure 1D ). Since the NS3-E176G substitution improved replication in the Gt 1b replicon background, this change was also added during amplification of Gt 1a clinical isolate sequences. In this Gt 1b background, replication was detected for all 10 Gt 1a chimeric replicons ( Figure 2E ), including five that previously had a <4-fold window in the Gt 1a (H77c) replicon background (Figure 2A ). The level of replication ranged from 53 to 133% of the Gt 1a (H77c) reference strain chimera. When transferred into the background of the Gt 1b (Con1) NS3-G176 replicon ( Figure 2F ), most Gt 1b clinical isolate chimeras replicated near the level of Gt 1b (Con1; 64-91%). Only one chimeric construct showed reduced replication (9% relative to Gt 1b [Con1]); this isolate still exhibited a robust assay window (1b-1, 156-fold).
Susceptibility of clinical isolate sequences to inhibition
All Gt 1a and Gt 1b clinical isolate chimeras were tested for susceptibility to HCV inhibitors using the optimized chimeric constructs (Table 1) . Overall, a 10-fold range in NS3 PI EC 50 values was observed for Gt 1a chimeras, from 0.4-fold to 4-fold that of the Gt 1a (H77c) chimera. For those constructs that replicated in both Gt 1a and Gt 1b backgrounds, 5-fold to 8-fold higher EC 50 values were obtained in the Gt 1b background, but the rank order of potency remained similar. For Gt 1b clinical isolate chimeras, most NS3 PI EC 50 values were similar to GT 1b (Con1; 0.4-fold to 1.5-fold) with the exception of isolate 1b-9 (58-fold higher). Among constructs that replicated in both Gt 1b NS3-E176 or NS3-G176 backgrounds, the relative order of potencies was similar but NS3 PI EC 50 values were about threefold higher in the NS3-G176 background. As a result of the invariant NS5B sequences, susceptibility to NS5B inhibitor varied less than threefold among all the Gt 1a and Gt 1b clinical isolate chimeras tested (Table 1) .
The phenotype for NS3 PI susceptibility in replicon cells was compared with that obtained in an in vitro NS3 protease enzyme assay measuring proteolytic activity of purified NS3 protease chimeras containing the NS3 protease domains from clinical isolates (see Methods). Overall, IC 50 values were lower and the range of values was compressed relative to that observed using the replicon. Gt 1a IC 50 values ranged from 0.6-fold to 1.6-fold that of Gt 1a (H77c). With the exception of isolate 1b-9, Gt 1b IC 50 values were 0.7-fold to 1-fold that of Gt 1b (Con1). The rank order of potency in the NS3 protease enzyme assay was similar but not identical to that observed in the replicon phenotyping assay. The Gt 1b chimera least susceptible to inhibition in the replicon assay (1b-9, 58-fold higher than Gt 1b [Con1]), was also least susceptible in the enzyme assay (56-fold).
Comparison of NS3 protease domain sequences from clinical isolates
Clinical isolate aa sequences were compared to identify polymorphisms that might account for differences in NS3 PI susceptibility. Variations in sequence from the reference strains are shown in Figure 3 . Alignment of the NS3 protease domain sequences revealed sequences 1b-1 and 1b-9 with considerable variation from the Gt 1b reference strain. These sequences, which were classified as Gt 1b using the Versant LiPA 2.0 assay (based on nucleotide similarity in the HCV 5′ untranslated and core regions [23] ), were more similar to Gt 1a sequences when aligned based on protease domain homology ( Figure 3A and 3C) , accounting for most of the apparent amino acid differences from the Gt 1b reference strain ( Figure 3B ).
Pre-existing amino acid polymorphisms at sites associated with NS3 PI resistance (shaded in grey in Figure  3A and 3B) were observed in Gt 1a and Gt 1b isolates at NS3 aa54, 80, 122, 168, and 170. Gt 1a isolates with higher NS3 PI EC 50 values (1a-6, 1a-7, 1a-8, 1a-9 and 1a-10) encoded NS3-K80. NS3-Q80 was present for Gt 1a (H77c) and most Gt 1a sequences with lower EC 50 values. An NS3-K80Q change introduced into the background of patient sequence 1a-10 resulted in a fourfold reduction in NS3 PI EC 50 value (5.2 ±0.6 nM, AKS et al., data not shown), demonstrating the contribution of NS3 aa80. The NS3 PI susceptibility of NS3 aa80 variants may be dependent on the NS3 protease sequence background, since minimal (twofold) effects were observed when an NS3-Q80K change was introduced into the Gt 1a (H77c) sequence (Additional file 5). A natural polymorphism exists at NS3 aa80: Gt 1a database sequences are divided approximately equally between Q and K, with R occurring infrequently; while Gt 1b database sequences encode predominantly Q, although K or L exist [24] . Introduction of NS3 aa80 variants seen in the database into the reference strains resulted in twofold to fourfold differences in EC 50 values (Additional file 4).
The sequence from patient 1b-9 was least susceptible to NS3 PI. The aa polymorphisms were identified at two positions associated with resistance to protease inhibitors, NS3-E168 and NS3-I170. The NS3-I170 variant was also seen in sequences from isolates 1b-1, 1b-4 and 1b-8, with NS3 PI EC 50 values more similar to Gt 1b (Con1; Table 1 ). The NS3-E168 variant is therefore the probable cause of reduced NS3 PI susceptibility, as Acid 7  14  26  35  40  42  48  61  62  64  66  67  71  72  85  86  89  91  102 it confers resistance on transfer into the Gt 1b (Con1) replicon (Figure 4 ).
Phenotypic resistance detection in mixed RNA populations
To test the ability of the replicon phenotyping assay to detect resistance, single aa changes known to confer NS3 PI resistance were introduced into the Gt 1a (H77c) or Gt 1b (Con1) reference strains. An NS3-R155K substitution has been associated with NS3-PI resistance in Gt 1a [25, 26] . Introduction of NS3-R155K into the Gt 1b replicon shuttle vector chimera containing a Gt 1a (H77c) NS3 protease domain (RLuc1b-S4 1a NS3-181) conferred 44-fold resistance to NS3 PI, confirming the ability to detect a Gt 1a resistance variant in the background of the Gt 1b replicon ( Figure 4A ). When NS3 PI resistance substitutions reported in Gt 1b [27] (NS3-D168E or NS3-D168V) were introduced into the Gt 1b NS3-G176 shuttle vector, 21-fold and 99-fold resistance to NS3 PI, respectively, was observed ( Figure 4B and 4C).
To understand the sensitivity of resistance detection, RNA encoding each NS3 PI resistant variant was mixed in increasing proportion with wild-type HCV replicon RNA, and transfected into Huh7.5 cells to monitor transient replication. Figure 4A , 4B and 4C depict NS3 PI dose-response curves obtained for mixed RNA populations encoding Gt 1a NS3-R155K, Gt 1b NS3-D168E or NS3-D168V. At intermediate doses, a plateau was observed in the dose-response curve for RNA mixtures encoding both wild-type and drug-resistant NS3 protease. This effect is probably the result of inhibition of wildtype and resistant sequences at differing concentrations, and is similar to that previously reported for Gt 1b resistance variants NS3-D168V and NS3-A156T [18] . Figure  4D (Gt 1a NS3-R155K), Figure 4E (Gt 1b NS3-D168E), and Figure 4F (Gt 1b NS3-D168V) plot the NS3 PI EC 50 and 90% effective concentration (EC 90 ) values obtained with increasing concentrations of variant RNA. For all three resistance substitutions, the EC 90 value was a more sensitive indicator of the presence NS3 PI resistance in a mixture than the EC 50 value. A change in EC 90 >3-fold was detected when RNA encoding ≥10% NS3-D168E or NS3-D168V, or ≥25% NS3-R155K was transfected. When assessing EC 50 value, at least 25% (NS3-D168E or NS3-D168V) to 50% (NS3-R155K) of RNA encoding resistance variants was required to distinguish phenotypic resistance. The apparent ratio of the EC 90 to the EC 50 increased when RNA mixtures contained both wild-type and variant RNA (Additional file 6). In phenotyping of uncharacterized isolates, measurement of the apparent EC 90 /EC 50 ratio could serve as an indicator of a mixed population containing drug-resistant variants.
Discussion
The high probability of pre-existing or rapidly emerging resistance substitutions during HCV infection has essentially prevented the use of DAA as monotherapy. This has profoundly influenced strategies for next-generation treatment regimens. Use of combination therapies in the context of the inherent variability of HCV sequences may result in resistance patterns that are not easily identified by sequence alone. Establishment of systems for the detection of phenotypic resistance will be essential to guide treatment. We developed a replicon system capable of phenotyping NS3 protease domain sequences from Gt 1a and Gt 1b clinical isolates. Lessons from establishment of this system can be applied to development of phenotyping systems for other HCV targets.
A key challenge to development of a phenotyping system was finding a replicon background capable of supporting replication of Gt 1a clinical isolates. Transfer of the NS3 protease domain into the background of a laboratory strain replicon has been described, but replication of isolates from Gt 1a patients was significantly reduced relative to those from Gt 1b patients [18] . Use of Gt 2a virus as a background successfully supported replication of some intergenotypic NS3 protease chimeras, but replication of Gt 1a and spread of both Gt 1a and Gt 1b were severely impaired [28] .
The Gt 1b replicon shuttle vector developed in these studies provided a facile, reproducible, and robust means of assessing the phenotype of clinically-derived Gt 1a and Gt 1b NS3 protease domain sequences. Transfer of Gt 1a clinical isolates to the Gt 1b background, combined with the cell culture adaptive change NS3-E176G, improved replication allowing quantitative measurement of effects on replication and inhibitor susceptibility for all clinical isolates tested.
When compared with phenotyping in an in vitro NS3 protease enzyme assay, a broader range in NS3 PI susceptibility was observed using the replicon. This may reflect differences in NS3 functions measured by the two systems. The enzyme assay measures cleavage of a simple peptide ester substrate mimetic cleaved more efficiently than similar peptides mimicking the NS4A/4B site. By contrast, the replicon assay requires NS3 protease cleavage at four sites in their native location within the HCV polyprotein. These cleavages could be affected by local polyprotein structure and the nature of the replication complex in cells. The replicon assay may magnify protease cleavage effects at multiple sites over time, or reveal effects on additional functions of NS3 during replication.
In our early efforts, achieving robust replication of clinical isolates was challenging, especially for Gt 1a NS3 sequences. An improvement in the percentage of replicating Gt 1a clones was achieved in our study. Another group [18] employed a replicon system with a cell culture adaptive change in NS4B, K1846T, while the current work used a replicon with an NS5A-S2204I that results in higher-level replication in our hands (AKS et al., data not shown). Engineering of cloning sites within the replicon resulted in reduced replication in the previous study, which may also have affected the level of replication of resulting patient isolate chimeras [18] .
To maximize sensitivity for detection of chimera replication, we chose replicon modifications that did not impair replication. Initial attempts to introduce several different changes in the Gt 1a and Gt 1b replicon shuttle vectors were unsuccessful. In some cases, nucleotide changes completely abolished replication. Changes to an NcoI site located within stem loop IIb of the HCV internal ribosome entry site had to be fine-tuned to avoid severely impairing replication (Additional file 3). Silent mutations to introduce a unique BglII site at the 3′ end of the NS3 protease domain also impaired replication (AKS et al., data not shown). For Gt 1a, the replicon did not tolerate introduction of a unique AscI site at the N-terminus of NS3 (Additional file 2), although addition of the AscI site and a resulting Gly at aa2 to a clone for expression of NS3 in E. coli did not impair enzyme activity (AKS et al., data not shown).
Because our system permitted phenotyping of all Gt 1a and Gt 1b clinical isolates tested, we were able to correlate differences in aa sequence with a range of inhibitor susceptibilities. NS3 protease variants were observed at aa associated with resistance, located in regions predicted to affect the structure of the extended substrate binding pocket. An NS3-E168 variant conferred resistance to NS3 PI. This aa change has the potential to disrupt an NS3-D168 salt bridge interaction with R155 important for binding in the P2 region of the substrate binding pocket [29] . We observed twofold to fourfold effects on NS3 PI potency depending on the NS3 aa80 variant tested. In the crystal structure of NS3, aa80 is positioned within the E1-F1 loop located above the catalytic triad and shown to be in close proximity to bulky NS3 PI P2 moieties [30] . Although the differences in susceptibility are in some cases modest, the effect of the natural variation in HCV isolate sequences on treatment outcome remains to be determined. In the replicon system, the presence of R, H or K at aa80 conferred enhanced resistance to some NS3 PIs when combined with NS3-R155 or NS3-D168 variants [31] .
We and others [10] [11] [12] [13] have observed naturally occurring polymorphisms reported to confer NS3 PI resistance in isolates from patients without prior PI therapy, highlighting the potential for pre-existing resistance to novel NS3 PIs. Combination therapies with NS3 PIs and DAA targeting other HCV genes, such as NS5A and NS5B, will be required to increase the resistance barrier in patients. In fact, DAA in combination with one another or with PEG-IFN/ RBV have been shown to reduce the rate of resistance in the replicon system [32, 33] , and are currently in clinical development. Chimeric replicon phenotyping assays have also been described for NS5B [34] . Developing assays to monitor emerging variants over larger regions of the HCV genome is likely to be technically more challenging due to requirements for cell culture adaptive changes in the replicon. To support combination clinical trials, such assays will be important for monitoring potential effects outside of the target genes and for understanding potential linkage of resistance variants.
